However, subgroup analysis for DFS yielded positive effects by capecitabine dosage (<1,000 mg or ≥1,000 mg), TNBC proportion (as subgroup or whole cohort), capecitabine sequence (in sequential or concurrent), study region (America–Europe or Asia), tumor size (≤2 cm or >2 cm), histological grade (1–2 or 3), and Ki-67 status (<30% or ≥30%). This evidence concerns the gene MKI67 and neoplasm.